Bionor Will Conduct Further Trials of HIV Vaccine, CEO Says
This article is for subscribers only.
Bionor Pharma ASA is proceeding with development of its experimental HIV vaccine even after it failed to keep patients off antiviral drugs in an early trial.
Buoyed by subsequent findings that the vaccine reduces the amount of virus that causes AIDS, Bionor is planning tests that it can finance on its own to confirm the results, and more extensive ones if it finds a partner, Chief Executive Officer Henrik Lund said yesterday in a telephone interview.